1. Anti–Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis 
Ran Chen, Pei-Chun Peng, Bin Wen, Fu-Ying Li, Sheng Xie, Guozhong Chen, Jiefu Lu, Zhuoyu Peng, Shao-Bo Tang, Yu-Mei Liang, Xin Deng 
Translational Oncology 
Volume 9, Issue 1, Pages (February 2016)
DOI: /j.tranon
Copyright © 2016 The Authors Terms and Conditions

2. Figure 1
Flowchart representing the systematic identification of studies.
Translational Oncology 2016 9, 32-40DOI: ( /j.tranon )
Copyright © 2016 The Authors Terms and Conditions

3. Figure 2 Assessment of risk bias.
Translational Oncology 2016 9, 32-40DOI: ( /j.tranon )
Copyright © 2016 The Authors Terms and Conditions

4. Figure 3
Forest plot depicting the overall response rate of nivolumab compared with chemotherapy.
Translational Oncology 2016 9, 32-40DOI: ( /j.tranon )
Copyright © 2016 The Authors Terms and Conditions

5. Figure 4
Forest plot depicting the comparison of adverse events associated with nivolumab and chemotherapy.
Translational Oncology 2016 9, 32-40DOI: ( /j.tranon )
Copyright © 2016 The Authors Terms and Conditions

6. Figure 5
Forest plot depicting the 1-year OS rates of nivolumab and dacarbazine.
Translational Oncology 2016 9, 32-40DOI: ( /j.tranon )
Copyright © 2016 The Authors Terms and Conditions

7. Figure 6
Forest plot depicting the PFS rates associated with nivolumab and dacarbazine.
Translational Oncology 2016 9, 32-40DOI: ( /j.tranon )
Copyright © 2016 The Authors Terms and Conditions

8. Figure 7
Forest plot depicting the objective response rates associated with nivolumab and dacarbazine.
Translational Oncology 2016 9, 32-40DOI: ( /j.tranon )
Copyright © 2016 The Authors Terms and Conditions

9. Figure 8
Forest plot depicting the comparison of adverse events associated with nivolumab and dacarbazine.
Translational Oncology 2016 9, 32-40DOI: ( /j.tranon )
Copyright © 2016 The Authors Terms and Conditions

10. Figure 9
Forest plot depicting the overall response rate with different doses (2 and 10 mg/kg) of pembrolizumab.
Translational Oncology 2016 9, 32-40DOI: ( /j.tranon )
Copyright © 2016 The Authors Terms and Conditions

11. Figure 10
Forest plot depicting the PFS rates associated with different doses (2 and 10 mg/kg) of pembrolizumab.
Translational Oncology 2016 9, 32-40DOI: ( /j.tranon )
Copyright © 2016 The Authors Terms and Conditions

12. Figure 11
Forest plot depicting 1-year survival rates associated with different doses (2 and 10 mg/kg) of pembrolizumab.
Translational Oncology 2016 9, 32-40DOI: ( /j.tranon )
Copyright © 2016 The Authors Terms and Conditions

13. Figure 12
Forest plot depicting overall response rates of different doses (0.3 and 2 mg/kg) of nivolumab.
Translational Oncology 2016 9, 32-40DOI: ( /j.tranon )
Copyright © 2016 The Authors Terms and Conditions

14. Figure 13
Forest plot depicting the PFS rates associated with different doses (0.3 and 2 mg/kg) of nivolumab.
Translational Oncology 2016 9, 32-40DOI: ( /j.tranon )
Copyright © 2016 The Authors Terms and Conditions

15. Figure 14
Forest plot depicting the OS rates associated with different doses (0.3 and 2 mg/kg) of nivolumab.
Translational Oncology 2016 9, 32-40DOI: ( /j.tranon )
Copyright © 2016 The Authors Terms and Conditions

16. Figure 15
Forest plot depicting the overall response rates associated with different doses (0.3 and 10 mg/kg) of nivolumab.
Translational Oncology 2016 9, 32-40DOI: ( /j.tranon )
Copyright © 2016 The Authors Terms and Conditions

17. Figure 16
Forest plot depicting PFS rates associated with different doses (0.3 and 10 mg/kg) of nivolumab.
Translational Oncology 2016 9, 32-40DOI: ( /j.tranon )
Copyright © 2016 The Authors Terms and Conditions

18. Figure 17
Forest plot depicting the OS rates associated with different doses (0.3 and 10 mg/kg) of nivolumab.
Translational Oncology 2016 9, 32-40DOI: ( /j.tranon )
Copyright © 2016 The Authors Terms and Conditions

19. Figure 18
Forest plot depicting the overall response rates associated with different doses (2 and 10 mg/kg) of nivolumab.
Translational Oncology 2016 9, 32-40DOI: ( /j.tranon )
Copyright © 2016 The Authors Terms and Conditions

20. Figure 19
Forest plot depicting the OS rates associated with different doses (2 and 10 mg/kg) of nivolumab.
Translational Oncology 2016 9, 32-40DOI: ( /j.tranon )
Copyright © 2016 The Authors Terms and Conditions

21. Figure 20
Forest plot depicting the PFS rates associated with different doses (2 and 10 mg/kg) of nivolumab.
Translational Oncology 2016 9, 32-40DOI: ( /j.tranon )
Copyright © 2016 The Authors Terms and Conditions